RxDoctor Payments DataLook up a doctor →

Cheryl Hull, MD

Dermatology · Rogers, ARNPI 1124081849

Payments from drug & device makers

$2,757,847in general payments, 2019–2025

Across 1,216 payments — averaging $2267.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$959K
  • Eli Lilly$481K
  • Incyte Corporation$459K
  • Bausch Health US, LLC$230K
  • AbbVie$190K
  • Dr.reddy's Laboratories,inc.$119K
  • plus $319K from 28 others
$3,669in research payments, 2019–2025

Across 6 payments — averaging $611.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$3K
  • Eli Lilly$969

What the payments were for

  • Consulting fees$82514%
  • Speaking & faculty fees$1,14520%
  • Food & beverage$3,85466%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,757,847 in reported general payments places this provider in the 95th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$475,104
Medicare patients
1,662
Services billed
7,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$293,875
OtezlaApremilast32$163,731
Dupixent PenDupilumab30$109,527
Taltz AutoinjectorIxekizumab13$88,755
Ketoconazole547$7,124
Clobetasol Propionate104$4,558
Tretinoin42$2,746
Acitretin11$2,412
Doxycycline Hyclate140$2,272
ZenataneIsotretinoin13$2,263
Metronidazole37$1,964
Triamcinolone Acetonide241$1,888
Fluorouracil27$1,783
Clindamycin Phosphate64$1,780
Tacrolimus20$1,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$18,723$163,73132 claims
Dr.reddy's Laboratories,inc.Zenatane$118,828$2,26313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 dermatology providers in Arkansas.

Other dermatology in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →